As a consequence, intra-tumor injection of a pan-RAR antagonist, which suppresses ATRA activity in the tumor micro-environment, promotes monocyte differentiation into antigen presenting cells, enhancing anti-tumor T cell responses. Here, RARA is linked to neoplasm.